{"schema_version":"secwatch.filing_event.v1","accession":"0001125345-23-000021","form_type":"8-K","ticker":"MGNX","cik":"0001125345","company_name":"MACROGENICS INC","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.929086+00:00","generated_at":"2026-06-19T13:10:18.435131+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MacroGenics reports preliminary Phase 1 lorigerlimab data; 28.6% PSA50 in mCRPC","bullets":["12 of 42 mCRPC patients (28.6%) achieved ≥50% PSA reduction; 9 of 42 (21.4%) achieved ≥90% PSA reduction.","9 of 35 evaluable patients (25.7%) had confirmed partial responses; median duration 4.6 months.","TRAEs in 86.6% of patients; grade ≥3 TRAEs in 34.6%; 24.4% discontinued due to AEs; no fatal TRAEs.","Company plans to initiate Phase 2 study in mCRPC in 2023.","Median prior therapies: 2; 83% had prior docetaxel, 81% prior androgen receptor antagonist."],"urls":{"canonical":"https://secwatch.observer/filing/0001125345-23-000021","json":"https://secwatch.observer/filing/0001125345-23-000021.json","markdown":"https://secwatch.observer/filing/0001125345-23-000021.md","text":"https://secwatch.observer/filing/0001125345-23-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000021/0001125345-23-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1125345/000112534523000021/mgnx-20230213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:10:18.435131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}